Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Several claims about kidney damage and susceptibility are generally consistent with label warnings/precautions about renal failure and renal impairment, but multiple specifics are not verifiable from the provided label excerpts (e.g., “changes in kidney filtration,” “toxins buildup,” “inflammation and scarring,” and a specific “>14 days” high-dose AKI timeframe). Monitoring recommendations are partially supported (hydration, renal impairment dose adjustment) but the label excerpt provided does not explicitly state that kidney function testing is essential or regular.
Category Scores
Accurate Statements
Long-term use of acyclovir may increase the risk of kidney damage.
Label excerpt includes: “Renal failure, in some cases resulting in death, has been observed with acyclovir therapy.” (Section 5 Warnings).
Monitoring kidney function during acyclovir therapy is essential to minimize the risk of kidney damage.
Label excerpt includes renal function linkage and adjustment: “The half-life and total body clearance of acyclovir are dependent on renal function. A dosage adjustment is recommended for patients with reduced renal function…” (Section 12).
Unsupported Statements
High-dose acyclovir therapy for more than 14 days is associated with an increased risk of acute kidney injury (AKI).
The provided label excerpts mention renal failure observed with therapy, but do not provide a time threshold (>14 days) or a specific “high-dose” association with “AKI.”
Patients with pre-existing kidney disease are more susceptible to acyclovir-induced kidney damage.
The label excerpts support renal impairment requiring dosage adjustment and mention renal failure and neuro/other symptoms marked particularly in renal impairment, but do not explicitly state “more susceptible” phrasing or acyclovir-induced kidney damage susceptibility as a direct statement.
Acyclovir may cause changes in the kidneys' ability to filter waste products, leading to a buildup of toxins in the blood.
Provided label excerpts do not describe “filtration changes” or “toxin buildup” mechanisms.
Acyclovir may cause inflammation and scarring in the kidneys, leading to permanent damage.
Provided label excerpts do not mention renal inflammation/scarring or permanent kidney damage as a mechanism/outcome.
Long-term use of acyclovir can increase the risk of kidney damage, particularly in patients with pre-existing kidney disease.
Label excerpts indicate renal failure observed with therapy and renal impairment requires dosage adjustment/caution, but do not explicitly link “long-term use” with increased risk, nor “particularly” in pre-existing kidney disease.
Patients should have their kidney function tested regularly during acyclovir therapy, particularly if they have pre-existing kidney disease or are receiving high-dose therapy.
The provided label excerpts emphasize dosage adjustment in renal impairment and caution with potentially nephrotoxic agents, but do not explicitly recommend “regular” kidney function testing or specify high-dose scenarios.
Contradictions
Low
AI Statement
None detected.
Label Reference
Important Omissions
When claiming monitoring/testing is essential, the label excerpts provided do not explicitly state a specific practice of “regular kidney function testing.”
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The core concept of renal failure/renal impairment considerations is present in the label excerpts, but several claims add unsupported specifics (AKI timing, mechanism descriptions, and regular testing instructions). These additions could mislead about the exact risk timeframe/mechanism and about monitoring frequency beyond what the provided label text explicitly states.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple kidney-damage claims are more specific than the provided label excerpts support (AKI >14 days, filtration/toxin buildup mechanism, inflammation/scarring/permanent damage, and explicit regular kidney testing recommendations).
Suggested Improvement
Rephrase to align with label excerpts: state that renal failure has been observed with acyclovir therapy and that renal function dependence requires dosage adjustment/caution in renal impairment, without adding unsupported mechanistic details or specific time/dose thresholds or explicit regular testing frequency unless directly present in the label.